SpirivaHandihaler
Phase 1Small molecule
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.SpirivaHandihaler is one of 32 small molecule programs targeting Fasting Conditions. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
35 competitors in Fasting Conditions
#DrugCompanyPhaseTrials
1Dynastat
PfizerPhase 3
Flomax
SanofiPhase 1
Jardiance
Boehringer IngelheimPhase 1
Monopril
Bristol-Myers SquibbPreclinical
Lamisil
NovartisPreclinical
Ambien
PPurdue Pharma LP
Preclinical
Jardiance
Boehringer IngelheimPhase 1
Anjeso
Boehringer IngelheimPreclinical
Isopto Carpine
AAdvanz Pharma
Preclinical
Plendil
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Fasting Conditions1 trial
A Trial to Assess the Bioequivalence of Tiotropium Bromide Inhalation Powder in Healthy Adult Participants Under Fasting Conditions
Active, not recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT06487416·186 enrolled
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT06487416·186 enrolledSources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SpirivaHandihaler. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details